eISSN 2288-3657
pISSN 2288-3649
pISSN 2288-3649
Currently ongoing clinical trials of TGF-β signaling pathway inhibitors for cancer treatment
| Drug name | Target type | Treatment | NCT number |
|---|---|---|---|
| Trabedersen (AP 12009) | TGF-β2AS-ODN | Advanced pancreatic, colorectal cancer, melanoma (phase I) | NCT00844064(completed) |
| Fresolimumab (GC1008) | TGF-β1 mAb | NSCLC (phase I/II) | NCT02581787 |
| AVID200 | TGF-β1/3 trap | Malignant solid tumor (phase I) | NCT03834662 |
| ABBV-151 | GARP/TGF-β1 mAb | Advanced or metastatic solid tumor (phase I) | NCT03821935 |
| SRK-181 | TGF-β1mAb | Advanced solid tumor (phase I); alone or in combination with anti-PD-L1 | NCT04291079 |
| Bintrafusp alfa (M7824) | TGF-β trap | Advanced NSCLC (phase III) | NCT03631706 |
| Biliary tract cancer (phase II/III) | NCT04066491 | ||
| Thymoma and thymic carcinoma (phase II) | NCT04417660 | ||
| Urothelial carcinoma (phase II) | NCT04501094 | ||
| HPV associated cancers (phase II) | NCT03427411 | ||
| Cervical cancer (phase II) | NCT04246489 | ||
| Triple-negative breast cancer (phase II) | NCT04489940 | ||
| Esophageal squamous cell carcinoma (phase II) | NCT04595149 | ||
| Advanced biliary tract cancer (phase II) | NCT03833661 | ||
| Head and neck squamous cell carcinoma (phase II) | NCT04428047 | ||
| Cervical cancer (phase II) | NCT04246489 | ||
| Advanced colorectal cancers (phase II) | NCT04491955 | ||
| Metastatic colorectal cancer (phase I/II) | NCT03436563 | ||
| Advanced Kaposi sarcoma (phase I/II) | NCT04303117 | ||
| Advanced pancreatic cancer (phase I/II) | NCT04327986 | ||
| Galunisertib (LY2157299) | TGF-β RI kinase inhibitor | Metastatic prostate cancer (phase II) | NCT02452008 |
| Advanced hepatocellular carcinoma (phase II) | NCT02178358 | ||
| Recurrent glioblastoma (phase II) | NCT01582269 | ||
| Advanced hepatocellular carcinoma (phase I) | NCT02906397 | ||
| Triple-negative breast cancer (phase I) | NCT02672475 | ||
| Carcinosarcoma of uterus or ovary (phase I); in combination with Paclitaxel/Carboplatin | NCT03206177 | ||
| Rectal adenocarcinoma (phase I) | NCT02688712 | ||
| Recurrent malignant glioma (phase I) | NCT01682187 | ||
| Vactosertib (TEW-7197) | TGF-β RI kinase inhibitor | Myeloproliferative neoplasms (phase II) | NCT04103645 |
| Metastatic colorectal or gastric cancer (phase I/II); in combination with Pembrolizumab | NCT03724851 | ||
| Advanced NSCLC (phase I/II); in combination with Durvalumab | NCT03732274 | ||
| Metastatic gastric cancer (phase I/II); in combination with Paclitaxel | NCT03698825 | ||
| Myelodysplastic syndrome (phase I/II) | NCT03074006 | ||
| Refractory multiple myeloma (phase I); in combination with Pomalidomide | NCT03143985 | ||
| Advanced desmoid tumor (phase I); in combination with Imatinib | NCT03802084 | ||
| Urothelial carcinoma (phase I); in combination with Durvalumab | NCT04064190(not yet recruiting) | ||
| PD-L1 positive NSCLC (phase II); in combination with Pembrolizumab | NCT04515979(not yet recruiting) | ||
| Pancreatic ductal adenocarcinoma (phase I);in combination with nal-IRI+5FU/LV | NCT04258072(not yet recruiting) |
AS-ODN, antisense oligonucleotides; NCT, National Clinical Trial; NSCLC, non-small cell lung cancer; mAb, monoclonal antibody; GARP, glycoprotein A repetitions predominant; anti-PD-L1, anti-programmed death-ligand 1; HPV, human papillomavirus; TGF-β-RI, TGF-β receptor type I; nal-IRI+5FU/LV, nanoliposomal irinotecan plus 5-fluorouracil/leucovorin. Data from ClinicalTrial.gov (https://www.clinicaltrials.gov/).
J Cancer Prev 2020;25:213~222 https://doi.org/10.15430/JCP.2020.25.4.213
© J Cancer Prev
Copyright © Korean Society of Cancer Prevention. All Rights Reserved. / Powered by INFOrang Co., Ltd